Agnico Eagle Mines heads into its October 28 earnings date with short sellers quietly rebuilding positions and options traders growing more defensive — a notable shift for a stock that has been a steady outperformer in precious metals.
The most striking data point this week is the pace of short interest accumulation. Borrowed shares have climbed 23% over the past week and are up more than 70% from a month ago, bringing SI to roughly 1.5% of the free float. That absolute level remains low — this is not a heavily shorted stock — but the rate of change is unusual for a large, diversified gold miner and deserves attention. The move coincides with AEM pulling back 2.4% on the week to $196.90, even as the one-month picture remains firmly positive at +5.6%. Despite the short rebuilding, the lending market is nowhere near stressed: availability is exceptionally loose at nearly 3,626%, meaning shares to borrow vastly outnumber shares already borrowed, and cost to borrow is running at just 0.63% — low by any measure. The short score nudged up to 30.3 from around 29.2 a week ago, a mild uptick that suggests growing but still modest bearish pressure.
Options positioning has also shifted more cautious. The put/call ratio climbed to 0.77, running above its 20-day average of 0.73 by more than one standard deviation. That places it close to the upper end of its year range, with the 52-week high at 0.82. The move in PCR mirrors the gradual upward drift visible in the history from early August — when the ratio was sitting near 0.62 — suggesting investors have been incrementally layering on downside protection over several weeks rather than making a sudden hedge. The setup reads as measured caution, not panic.
The Street remains constructive on AEM but has been trimming expectations. The analyst consensus sits at buy, with a mean price target around $217 — roughly 10% above the current price. The most recent move came from JP Morgan in early August, which nudged its target to $179 while holding a Neutral rating; that target looks stale relative to where the stock trades, and the gap between JP Morgan's cautious $179 and BofA's Buy-rated $240 captures the breadth of the debate. A cluster of target reductions in July — from Barclays, Scotiabank, RBC and BofA — left the consensus range wide but still skewed toward upside. On valuation, the PE has ticked up modestly over 30 days to around 15.9x while EV/EBITDA has eased slightly to 8.6x, suggesting the market is paying incrementally more for earnings even as the stock gave back some of its recent gains. Factor scores are mixed: EPS surprise ranks in the 72nd percentile, reflecting a solid beat history, but EPS momentum over both 30 and 90 days is weak, ranking in the bottom quintile of the universe.
Institutional ownership is broad and incrementally growing. BlackRock leads at 5.7% of shares, with Capital Research and VanEck also among the top holders — the latter reflecting gold ETF flows. All three added to positions in the most recent reporting period. Insider activity is modest and mildly negative: the 90-day net value of insider transactions is roughly minus $735,000 in USD terms, driven by a handful of small discretionary sells from directors, with the buys in June coming in at negligible size. Nothing in the insider register signals conviction in either direction.
Earnings history adds useful context. The last print on July 30 produced a muted one-day move of less than 1%, but the stock gained more than 16% in the five sessions that followed. The prior quarter's result in May went the other way — the stock fell 4.4% on the day before recovering partially over the following week. With the October 28 date now six weeks out, the positioning setup — rising short interest at a contained level, above-average put/call ratio, subdued momentum scores — will be worth tracking to see whether it intensifies as the announcement approaches or fades on any gold price strength.
See the live data behind this article on ORTEX.
Open AEM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
